Nuvation Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nuvation Bio (NUVB).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

2S.Buy

11Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$11Upside to Avg. PT+132.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$12
Sep 16, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$10
Sep 16, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Aug 21, 2026	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
Aug 18, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$13
Aug 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$19→$20
Jul 27, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$17→$21
Jul 23, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$20→$19
Jul 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$12→$13
May 5, 2026	RBC Capital	Leonid Timashev	Maintained	Outperform	$20
May 5, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
May 5, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$17
Apr 16, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Apr 2, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Mar 27, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Mar 3, 2026	UBS	Michael Yee	PT Cut	Neutral	$10→$7
Mar 3, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$12→$13
Feb 10, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$11
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$9→$12

Analyst Ratings News

This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on EXPD ($180); Equal-Weight on SFD ($22).

Avi Kapoor

PRO
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12

Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target

Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and maintains $10 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.

Benzinga Newsdesk

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.

Avi Kapoor

This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated coverage on Builders FirstSource, Inc and Nuvation Bio Inc.

Avi Kapoor

Nuvation Bio Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Nuvation Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PRO
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12

PRO
Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target

PRO
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

People Also Watch

People Also Watch

Nuvation Bio Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Nuvation Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

PROCitigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12

PROCitizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target

PROWedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

People Also Watch

People Also Watch

PRO
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12

PRO
Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price Target

PRO
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target